- Language: English
- 1113 Pages
- Published: July 2012
- Region: Global
The Future of Nutrigenomics: New Opportunities in Personalized Nutrition and Food-pharma Collaboration
- Published: January 2010
- Region: Global
- 151 Pages
- Scripp Business Insights
Nutrigenomics explores how nutrients or bioactive dietary compounds can influence gene expression and an individuals risk to certain diseases. Nutrigenetics is the study of how variations in an individual’s genetic makeup can increase or decrease the need for a specific nutrient or bioactive food component.
Nutrigenomics has the potential to impact various parts of the food chain including the genetic modification of crops and animal feeds, the development of nutrigenomic tests to monitor food safety and personalization of diets, as well as the identification of nutritional supplements and nutrigenomic based products which may offer potential health benefits.
The consumer environment is driving growth in the Nutrition & Health market. Over the past decade, consumers have become more concerned for their health and are increasingly inclined to invest in DTC nutrigenetic tests to assess their risk of disease and obtain dietary advice. Healthcare providers too, are keen to shift some of the burden of healthcare costs to individuals and recognize that the personalization of nutrition may be beneficial. The Health and nutrition market is currently worth around $485 billion.
This report reviews the business strategies of leading companies regarding the adoption of nutrigenomic technologies and establishment of public-private partnerships as well as potential opportunities for biomarker discovery with the pharma and diagnostic industry to personalize nutrition and medicine.
Key features of this report
- Identify leading academic groups and companies at the forefront of the nutrigenomic research who will drive the market towards a more personalized approach to nutrition and disease prevention.
- Assess the nutrigenomic testing market, leading companies and its role in empowering consumers to take a more active role in making dietary decisions and maintaining their health status
- Review the backgrounds, strategies and business models of companies and assess potential opportunities to collaborate with the pharma and diagnostic industry.
Scope of this report
- Identify the companies leading the field in nutrigenomic research from ingredient & food manufacturers to nutrigenomic testing companies
- Review their key products and business alliances which enable them to participate in this evolving field of science
- Identify points of convergence of the pharma, diagnostic and food and drinks markets which may offer new opportunities for co development
- Review market drivers regarding the adoption of nutrigenomic information and the personalization of nutrition.
Key Market Issues
- The food market is changing: Over the past decade, consumers have become more concerned for their health and wellbeing. The roll of the food and drinks industry is changing and shifting towards a more benefit driven and preventative approach. In order to respond to market dynamics the companies have needed to adopt an “open network” model to gain access to innovative research and technologies which will drive future product development.
- Nutrigenomics & pharmacogenomics are related in their approach to identify subpopulations that respond to treatment/nutrition. The application of these technologies may lead to the identification of old and new ingredients that have beneficial effects for specific consumer groups, helping to maintain health and wellness and leading to the personalization of treatment and diets. The scientific evidence is mounting however, large scale clinical studies are needed to reinforce data which can be utilized initially in dietary guidance and latterly to support health claims.
- Nutrigenomic testing marketing is growing and has been fueled by consumer concerns for their health and the demand for genomic information. Increasingly,consumers are inclined to invest in DTC nutrigenomic tests to assess their health status and obtain dietary guidance. This market is currently estimated to be worth US$730 million and growing by 20% per annum.
Key findings from this report
- The food and drinks industry has been undergoing major regulatory changes during the last few years, particularly with respect to health and dietary claims. Added to this, the adoption and application of nutrigenomic technologies, may provide additional clinical data to substantiate claims and provide new opportunities to develop products which target consumer sub groups. This may require further adjustments in the regulatory framework to stimulate innovation but ensure consumer safety.
- There are significant market opportunities for the development of nutrigenomic tests and products which target consumer groups. Successful products will need to be supported by robust and reproducible clinical studies - these will cost time and money and will only be feasible through public / private collaborations. The results will enable the manufacturer to clearly differentiate themselves and target specific groups – leading to fragmentation of the market and a shift in he healthcare paradigm from treatment towards prevention.
- Synergies exist between the food and drinks industry and the pharma and diagnostic industry that may create opportunities (e.g. biomarker discover) but also lead to conflicts as the food manufacturers aim to keep consumers healthier for longer forcing pharma to switch to a more preventative strategy by targeting lifestyle disease (e.g. obesity) as their pool of unhealthy ill patients contracts.
Key questions answered
- Which companies are involved in nutrigenomic testing and how may they influence the uptake of personalised nutrition?
- How are Health and Nutrition market leaders applying nutrigenomic research in their R&D programs to develop new products or create new marketing opportunities?
- What potential opportunities exist between the food and drinks industry and the pharma and diagnostic industry to co-develop biomarkers for the development of personalised nutrition and medicine. SHOW LESS READ MORE >
The Future of Nutrigenomics
Collaborative nutrigenomic research & consortia
Leading food & drinks companies: nutrigenomic strategies
Leading nutrigenomic testing companies
Opportunities: convergence of pharma & diagnostics
Challenges: regulation, ethical & IP issues
Chapter 1 Defining nutrigenomics
Nutrigenomics and the food & drinks industry
Nutrigenomics & food products
Nutrigenomics & personalized nutrition
Chapter 2 Market drivers
Drivers for personalized nutrition
Chronic non-communicable disease
Urbanization and the emerging markets
Global health economics
Conclusions on drivers for personalized nutrition
Chapter 3 Collaborative nutrigenomic research & consortia
Nutrigenomic research consortia
Nutrigenomic research in the EU
The European Nutrigenomics Organization (NuGO)
TI Food and Nutrition
Vision EpiFood Project
Canada Foundation for Innovation (CFI)
Public-private in age-related diseases
Nutrigenomic research in the US
Public-private partnership: genetically modified crops
Nutrigenomic research across the world
International Society of Nutrigenetics/Nutrigenomics (ISNN)
Chapter 4 Leading food & drinks companies: nutrigenomic strategies
Ingredients manufacturers approach to nutrigenomics
Food manufacturers’ approach to nutrigenomics
Pharma industry M&A in consumer nutrition
The evolving open network model
Areas for market growth & time scales
Chapter 5 Leading nutrigenomic testing companies
Interleukin Genetics Inc
Chapter 6 Opportunities: convergence of pharma & diagnostics
Nutrigenomics vs pharmacogenomics
Global health issues treatment vs prevention
Convergence of the pharmaceutical & diagnostic market
Chapter 7 Challenges: regulation, ethical & IP issues
Regulation of nutrigenomic foods
Regulation of nutrigenomic tests
Public awareness & perceptions
Chapter 8 Conclusions
The food & drinks market
Global genetic testing market
Primary research methodology
List of Figures
Figure 1.1: Nutrigenetics and nutrigenomics
Figure 1.2: The ‘omics technologies
Figure 1.3: The functional genomic tool box
Figure 1.4: Applications of nutrigenomics in the food chain
Figure 2.5: Drivers for the food & drinks industry
Figure 2.6: The ageing population a driver for personalized nutrition
Figure 2.7: Personalized nutrition targeting consumer segments
Figure 2.8: Population over 60: world and developed regions (1950-2050)
Figure 2.9: Nutritional challenges – obesity & metabolic syndrome
Figure 2.10: Growth in consumers in developing & emerging countries (2008-2018)
Figure 2.11: Healthcare expenditure as a share of GDP (2006)
Figure 2.12: Target population of nutrigenomic based products
Figure 4.13: BASF approach to gene discovery
Figure 4.14: DSMs sales growth targeting four emerging business areas
Figure 4.15 DSMs R&D competencies
Figure 4.16 An International and interdisciplinary network
Figure 4.17 Diversify & de-risk through externalization
Figure 4.18 Open network model
Figure 4.19: Waves of nutrigenomic development
Figure 5.20: WellGen’s nutrigenomic based discovery
Figure 6.21: Nutrigenomics vs pharmacogenomics
Figure 6.22: Relationship of drugs, disease, genes and gene products
Figure 8.23: Health and nutrition market segments (2009)
Figure 8.24: Nutrigenomic impact on personalized nutrition
List of Tables
Table 3.1: European Consortia and Nutrigenomic Research Programs
Table 3.2: Nutrigenomics Network Programs
Table 4.3: Stakeholders in nutrigenomic research and personalized nutrition
Table 4.4: Chr Hansen - strategic alliances & investments
Table 4.5: Nestlé nutrigenomic alliances & investments
Table 4.6: Divestment of Animal, Consumer & Medical Nutrition Divisions
Table 4.7: Consumer Health Divisions of Pharmaceutical Companies
Table 4.8: Alliance between Food, Pharma, Biotech and the Diagnostic Industries
Table 5.9: Categorization of genetic variations that may be included in nutrigenomic tests
Table 5.10: Categorization of genetic variations that may be included in nutrigenomic tests
Table 6.11: Known diet- gene interactions
Table 6.12: Known gene-nutrient interactions
- Chr. Hansen
- Gene Smart
- Genova Diagnostics
- Interleukin Genetics Inc